Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cancer Immunotherapy Linked To Increased Risk Of Rheumatologic Disorders



Due to the nature of immunotherapy treatments, researchers had previously only expected the drugs to exacerbate preexisting rheumatologic symptoms.

Share this!

Tweet: Researchers find link between immunotherapy and rheumatologic disorders http://ctt.ec/fVC6e+Researchers find connection between immunotherapy and rheumatologic disorders.

Tweet: 1.3% of patients receiving immunotherapy showed rheumatologic symptoms http://ctt.ec/P2YW3+1.3% of patients receiving immunotherapy showed rheumatologic symptoms.

June 28, 2016 | by Sarah Massey, M.Sc.

A recent study conducted by Johns Hopkins University researchers has found a connection between cancer immunotherapy treatments and an increased risk of developing rheumatologic disorders, such as arthritis. Due to the nature of immunotherapy treatments, researchers had previously only expected the drugs to exacerbate preexisting rheumatologic symptoms.

In the largest study of its kind to date, Johns Hopkins researchers found that between 2012 and 2016, 1.3 percent of patients receiving cancer immunotherapy reported suffering from a rheumatologic disease as a result. Based on a relatively small sample size of 13 patients, the researchers concluded that immunotherapy drugs used alone, or in combination with other treatments, could lead to a higher than normal risk of rheumatologic disorders.

“I don't think anyone is particularly surprised that rheumatologic disorders might be a complication of drugs that boost the immune system,” said Dr. Laura Cappelli, rheumatologist at the Johns Hopkins University School of Medicine, and an author on the study. According to Cappelli, the study may even have underestimated the number of cases of rheumatologic disorders, as symptoms such as mild joint pain may have gone undiagnosed.

The researchers say that further studies will need to be performed in order to confirm a causal link between immune checkpoint inhibitors and rheumatologic disorders. Cappelli is urging physicians and patients to consider both the potential benefits and risks of immunotherapy drugs before starting treatment, and to monitor for signs of rheumatologic symptoms so that action may be taken to limit joint damage.

All 13 patients treated at the Johns Hopkins Kimmel Cancer Center were receiving Bristol-Myers Squibb’s Yervoy (ipilimumab) or Opdivo (nivolumab), either alone or in combination. These patients developed symptoms consistent with arthritis, or with a combination of autoimmune symptoms including dry eyes and mouth, known as sicca syndrome.

“In 2015, our rheumatology clinic started getting more and more referrals from our oncology department to evaluate patients treated with immunotherapies,” said Cappelli. “And the patients we saw had very severe, highly inflammatory arthritis. They needed even higher doses of steroids to control their symptoms compared to what is needed in other forms of inflammatory arthritis, like rheumatoid arthritis.”

The researchers point out that clinical trials of the immunotherapy drugs found an increased risk of rheumatologic conditions such as inflammatory bowel diseases, lung inflammation, autoimmune thyroid disease and pituitary gland inflammation. Cappelli and her colleagues plan to continue to monitor the incidence of rheumatologic disease among immunotherapy patients, to try to identify what makes some patients more likely to develop these symptoms, compared to others.

Keywords: Cancer, Immunotherapy, Arthritis


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.